{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:01:14Z","timestamp":1761843674862},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":4422,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1093\/annonc\/mdm347","type":"journal-article","created":{"date-parts":[[2007,9,7]],"date-time":"2007-09-07T01:04:41Z","timestamp":1189127081000},"page":"1810-1816","source":"Crossref","is-referenced-by-count":29,"title":["Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I\/II study in first-line treatment of metastatic colorectal cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"E.","family":"Bajetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Celio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mancin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bajetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm347_bb0010","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/annonc\/mdh383","article-title":"New options and old dilemmas in the treatment of patients with advanced colorectal cancer","volume":"15","author":"Punt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0015","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2002.08.015","article-title":"A triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial","volume":"20","author":"Souglakos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0020","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","article-title":"Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer","volume":"20","author":"Falcone","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"key":"10.1093\/annonc\/mdm347_bb0030","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III trial","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0035","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0040","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cncr.11910","article-title":"Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma","volume":"15","author":"Bajetta","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm347_bb0050","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdi227","article-title":"A phase I\/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer","volume":"16","author":"Rea","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0055","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdl179","article-title":"Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study","volume":"17","author":"Koopman","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0060","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0070","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1026535824044","article-title":"Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients","volume":"11","author":"Goldwasser","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines)","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm347_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdm347_bb0085","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"issue":"18S","key":"10.1093\/annonc\/mdm347_bb0090","volume":"24","author":"Falcone","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1091-255X(02)00121-X","article-title":"Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases","volume":"7","author":"Allen","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"10.1093\/annonc\/mdm347_bb0100","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/annonc\/dkf281","article-title":"Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I\/II study in first-line treatment of patients with advanced colorectal cancer","volume":"13","author":"Scheithauer","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm347_bb0105","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/cncr.21874","article-title":"Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer","volume":"106","author":"Hoff","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm347_bb0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1054\/bjoc.2000.1600","article-title":"Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines","volume":"84","author":"Fischel","year":"2001","journal-title":"Br J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/11\/1810\/574316\/mdm347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:17:42Z","timestamp":1582204662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419411423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0923753419411423"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm347","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}